Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAPNASDAQ:CRVONASDAQ:IGMSNASDAQ:MTEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.29-0.3%$0.26$0.20▼$1.48$76.34M2.861.73 million shs248,432 shsCRVOCervoMed$7.40-2.5%$9.08$1.80▼$22.57$64.80M-0.231.33 million shs74,003 shsIGMSIGM Biosciences$1.26+0.9%$1.22$0.92▼$22.50$75.62M0.61310,275 shs78,086 shsMTEXMannatech$10.20-3.8%$9.80$6.75▼$16.49$19.39M1.064,419 shs281 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics+1.37%+3.03%+1.01%-42.98%-73.01%CRVOCervoMed-6.99%-4.65%-25.95%+251.39%-61.39%IGMSIGM Biosciences-0.79%+2.46%-7.41%-7.41%-85.28%MTEXMannatech+8.66%+4.79%+5.11%-10.23%+35.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAPAdaptimmune Therapeutics2.8712 of 5 stars4.23.00.00.03.30.80.0CRVOCervoMed3.4199 of 5 stars4.43.00.00.02.61.70.6IGMSIGM Biosciences4.1252 of 5 stars3.01.00.04.62.63.31.3MTEXMannatech0.9341 of 5 stars0.04.00.00.02.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 2.43Hold$1.52427.20% UpsideCRVOCervoMed 2.89Moderate Buy$27.63273.26% UpsideIGMSIGM Biosciences 1.90Reduce$5.50336.16% UpsideMTEXMannatech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MTEX, IGMS, CRVO, and ADAP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ADAPAdaptimmune TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.005/14/2025ADAPAdaptimmune TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.465/13/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/12/2025CRVOCervoMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $15.004/11/2025ADAPAdaptimmune TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/1/2025ADAPAdaptimmune TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $3.003/26/2025ADAPAdaptimmune TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $1.753/26/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/21/2025ADAPAdaptimmune TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $1.503/21/2025ADAPAdaptimmune TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$3.15 ➝ $1.403/18/2025CRVOCervoMedRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$179.64M0.42N/AN/A$0.17 per share1.69CRVOCervoMed$7.14M9.02N/AN/A$1.30 per share5.69IGMSIGM Biosciences$2.68M28.11N/AN/A$3.46 per share0.36MTEXMannatech$115.04M0.17N/AN/A$5.64 per share1.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$113.87M-$0.27N/AN/AN/A-25.43%-74.15%-15.09%8/11/2025 (Estimated)CRVOCervoMed-$2.17M-$2.18N/AN/AN/A-118.68%-44.11%-39.81%8/8/2025 (Estimated)IGMSIGM Biosciences-$246.42M-$3.27N/AN/AN/A-7,534.03%-155.42%-61.04%8/13/2025 (Estimated)MTEXMannatech-$2.24M-$0.10N/A∞N/A-1.26%-15.62%-3.76%8/11/2025 (Estimated)Latest MTEX, IGMS, CRVO, and ADAP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ADAPAdaptimmune Therapeutics-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million5/13/2025Q1 2025IGMSIGM Biosciences-$0.41-$0.86-$0.45-$0.86$4.25 million$0.50 million5/13/2025Q1 2025MTEXMannatechN/A-$0.80N/A-$0.80N/A$26.56 million5/12/2025Q1 2025CRVOCervoMed-$0.60-$0.56+$0.04-$0.56$1.70 million$1.92 million3/26/2025Q4 2024MTEXMannatechN/A$1.20N/A$1.20N/A$29.01 million3/24/2025Q4 2024ADAPAdaptimmune Therapeutics-$0.17-$0.26-$0.09-$0.29$16.56 million$3.22 million3/17/2025Q4 2024CRVOCervoMed-$0.67-$0.80-$0.13-$0.80$1.51 million$2.16 million3/6/2025Q4 2024IGMSIGM Biosciences-$0.74-$0.61+$0.13-$0.61$0.39 million$0.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/AIGMSIGM BiosciencesN/AN/AN/AN/AN/AMTEXMannatech$0.201.96%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune Therapeutics0.623.853.82CRVOCervoMedN/A15.0415.04IGMSIGM BiosciencesN/A5.225.22MTEXMannatech0.441.250.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%CRVOCervoMed25.15%IGMSIGM Biosciences42.79%MTEXMannatech12.98%Insider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.74%CRVOCervoMed35.40%IGMSIGM Biosciences57.00%MTEXMannatech41.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490265.05 million224.05 millionOptionableCRVOCervoMed48.70 million3.93 millionNot OptionableIGMSIGM Biosciences19059.78 million25.57 millionOptionableMTEXMannatech2501.90 million1.10 millionNot OptionableMTEX, IGMS, CRVO, and ADAP HeadlinesRecent News About These CompaniesMannatech Premieres Powerful New Documentary on Marathon Legend Steve EdwardsMay 21, 2025 | businesswire.comMannatech Reports Financial Results for First Quarter 2025May 13, 2025 | businesswire.comAstronova outlines fiscal 2026 growth targets driven by aerospace and PI segment advancementsApril 14, 2025 | msn.comMannatech Reports Fourth Quarter 2024 Financial ResultsMarch 26, 2025 | businesswire.comMannatech Stock Soars to 52-Week High, Hits $16 MarkJanuary 30, 2025 | msn.comMannatech names Robert Toth vice chairman of the boardNovember 27, 2024 | markets.businessinsider.comMannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of DirectorsNovember 26, 2024 | businesswire.comMannatech Inc. Q3 Earnings SummaryNovember 13, 2024 | markets.businessinsider.comMannatech Reports Financial Results for Third Quarter 2024November 12, 2024 | businesswire.comTrading (MTEX) With Integrated Risk ControlsOctober 17, 2024 | news.stocktradersdaily.com(MTEX) Investment AnalysisOctober 6, 2024 | news.stocktradersdaily.comMannatech, Incorporated (NASDAQ:MTEX) Director Sells $126,232.00 in StockSeptember 12, 2024 | insidertrades.comDirector Tyler Rameson Acquires 16,288 Shares of Mannatech Inc (MTEX)September 11, 2024 | finance.yahoo.com(MTEX) Trading SignalsAugust 19, 2024 | news.stocktradersdaily.comMannatech Reports Financial Results for Second Quarter 2024August 13, 2024 | finance.yahoo.comHow To Trade (MTEX)July 29, 2024 | news.stocktradersdaily.com(MTEX) Long Term Investment AnalysisJuly 19, 2024 | news.stocktradersdaily.comMTEX Stock Earnings: Mannatech Reported Results for Q1 2024May 15, 2024 | investorplace.comMannatech Reports Financial Results for First Quarter 2024May 14, 2024 | businesswire.comMannatech expands into Thailand, targets ASEAN growthApril 26, 2024 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTEX, IGMS, CRVO, and ADAP Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAP$0.29 0.00 (-0.28%) As of 12:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.CervoMed NASDAQ:CRVO$7.40 -0.19 (-2.49%) As of 12:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.IGM Biosciences NASDAQ:IGMS$1.26 +0.01 (+0.88%) As of 12:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Mannatech NASDAQ:MTEX$10.20 -0.40 (-3.77%) As of 12:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Tesla’s Lofty 200 P/E Could Mean More Upside Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
